Literature DB >> 23795946

MYC status determination in aggressive B-cell lymphoma: the impact of FISH probe selection.

Ana M Muñoz-Mármol1, Carolina Sanz, Gustavo Tapia, Ruth Marginet, Aurelio Ariza, José L Mate.   

Abstract

AIMS: To assess how hybridization probe design may affect MYC status determination in Burkitt lymphoma and diffuse large B-cell lymphoma. METHODS AND
RESULTS: We compared the results obtained with one dual-fusion and two break-apart commercial probes in a retrospective series of 91 aggressive B-cell lymphomas. All three probes were able to detect the IGH-MYC translocation in every case bearing it (13/13). However, seven of 13 (54%) non-IGH-MYC (light-chain immunoglobulin or non-immunoglobulin-MYC) rearrangements were unambiguously detected by just one of the probes tested. On the other hand, when the IGH-MYC dual-fusion probe was used, nine of 15 (60%) cases with a hybridization pattern suggestive of a non-IGH-MYC translocation were attributable to MYC copy gain rather than MYC rearrangement, as demonstrated by both break-apart probes.
CONCLUSIONS: Taking into account the prognostic and therapeutic implications of the MYC translocation, probe design and limitations should be particularly kept in mind when MYC hybridization patterns are interpreted. In our experience, detection of 8q24 abnormalities could be optimized by a two-probe approach involving the application of both IGH-MYC dual-fusion and MYC break-apart selected kits.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  Burkitt lymphoma; MYC; break-apart; diffuse large B-cell lymphomas; dual-fusion; fluorescence in-situ hybridization; translocation

Mesh:

Substances:

Year:  2013        PMID: 23795946     DOI: 10.1111/his.12178

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  19 in total

Review 1.  Genomics of aggressive B-cell lymphoma.

Authors:  Allison Rosenthal; Lisa Rimsza
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  False-negative rates for MYC fluorescence in situ hybridization probes in B-cell neoplasms.

Authors:  Rebecca L King; Ellen D McPhail; Reid G Meyer; George Vasmatzis; Kathryn Pearce; James B Smadbeck; Rhett P Ketterling; Stephanie A Smoley; Patricia T Greipp; Nicole L Hoppman; Jess F Peterson; Linda B Baughn
Journal:  Haematologica       Date:  2018-12-06       Impact factor: 9.941

3.  Prognostic impact of MYC protein expression in central nervous system diffuse large B-cell lymphoma: comparison with MYC rearrangement and MYC mRNA expression.

Authors:  Seung-Myoung Son; Sang-Yun Ha; Hae-Yong Yoo; Dongryul Oh; Seok-Jin Kim; Won-Seog Kim; Young-Hyeh Ko
Journal:  Mod Pathol       Date:  2016-09-30       Impact factor: 7.842

Review 4.  The clinicopathologic spectrum of mature aggressive B cell lymphomas.

Authors:  Lisa Rimsza; Stefania Pittaluga; Stephan Dirnhofer; Christiane Copie-Bergman; Laurence de Leval; Fabio Facchetti; Stefano Pileri; Andreas Rosenwald; Andrew Wotherspoon; Falko Fend
Journal:  Virchows Arch       Date:  2017-08-26       Impact factor: 4.064

5.  Comparison Between Integrated Genomic DNA/RNA Profiling and Fluorescence In Situ Hybridization in the Detection of MYC, BCL-2, and BCL-6 Gene Rearrangements in Large B-Cell Lymphomas.

Authors:  Daniel P Cassidy; Jennifer R Chapman; Rafael Lopez; Kyle White; Yao-Shan Fan; Carmen Casas; Eric A Severson; Francisco Vega
Journal:  Am J Clin Pathol       Date:  2020-02-08       Impact factor: 2.493

Review 6.  Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma.

Authors:  R Andrew Harkins; Andres Chang; Sharvil P Patel; Michelle J Lee; Jordan S Goldstein; Selin Merdan; Christopher R Flowers; Jean L Koff
Journal:  Expert Rev Hematol       Date:  2019-09-12       Impact factor: 2.929

Review 7.  Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma.

Authors:  Rebecca L King; Eric D Hsi; Wing C Chan; Miguel A Piris; James R Cook; David W Scott; Steven H Swerdlow
Journal:  Virchows Arch       Date:  2022-09-03       Impact factor: 4.535

8.  High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology.

Authors:  Lauren C Chong; Susana Ben-Neriah; Graham W Slack; Ciara Freeman; Daisuke Ennishi; Anja Mottok; Brett Collinge; Pau Abrisqueta; Pedro Farinha; Merrill Boyle; Barbara Meissner; Robert Kridel; Alina S Gerrie; Diego Villa; Kerry J Savage; Laurie H Sehn; Reiner Siebert; Ryan D Morin; Randy D Gascoyne; Marco A Marra; Joseph M Connors; Andrew J Mungall; Christian Steidl; David W Scott
Journal:  Blood Adv       Date:  2018-10-23

9.  The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma.

Authors:  Neeraj Sharma; James B Smadbeck; Nadine Abdallah; Cinthya Zepeda-Mendoza; Moritz Binder; Kathryn E Pearce; Yan W Asmann; Jess F Peterson; Rhett P Ketterling; Patricia T Greipp; P Leif Bergsagel; S Vincent Rajkumar; Shaji K Kumar; Linda B Baughn
Journal:  Clin Cancer Res       Date:  2021-10-01       Impact factor: 12.531

10.  Robust detection of translocations in lymphoma FFPE samples using targeted locus capture-based sequencing.

Authors:  Mark Pieterse; Joost Swennenhuis; G Tjitske Los-de Vries; Amin Allahyar; Mehmet Yilmaz; Roos Leguit; Ruud W J Meijers; Robert van der Geize; Joost Vermaat; Arjen Cleven; Tom van Wezel; Arjan Diepstra; Léon C van Kempen; Nathalie J Hijmering; Phylicia Stathi; Milan Sharma; Adrien S J Melquiond; Paula J P de Vree; Marjon J A M Verstegen; Peter H L Krijger; Karima Hajo; Marieke Simonis; Agata Rakszewska; Max van Min; Daphne de Jong; Bauke Ylstra; Harma Feitsma; Erik Splinter; Wouter de Laat
Journal:  Nat Commun       Date:  2021-06-07       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.